HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model.

Abstract
We were interested to investigate if a combination of a modified tissue-type plasminogen activator, SUN9216, which is constructed by modifying a single amino acid (Asn117-Gln117) to yield a tissue-type plasminogen activator lacking finger and growth factor domains with a long half-life in blood, and an endothelin receptor antagonist, FR139317, (R)2-[(R)-2-[(S)-2[[1-(hexahydro-1H-azepinyl)]carbonyl]amino-4- methyl-pentanoyl]amino-3-[3-(1-methyl-1H-indolyl)]propionyl)amino-3- (2-pyridyl)propionic acid, has greater thrombolytic efficacy than a thrombolytic agent alone in reducing the size of cerebral infarction. The thrombotic occlusion of the rat middle cerebral artery was induced by a photochemical reaction between rose bengal and green light, which causes endothelial injury followed by platelet adhesion and formation of a platelet-rich thrombus. SUN9216 (1 mg/kg) was injected intravenously 30 min after the middle cerebral artery occlusion and the time for reopening of the middle cerebral artery by SUN9216 was monitored for a 60-min period under an operating microscope. In the rats in which thrombolysis was achieved with SUN9216, the size of the cerebral infarction was significantly (P < 0.05) reduced as compared with that in the rats treated with saline and was comparable to the reduction produced by the combination doses. It is concluded that, under the present experimental conditions, endothelin may not be involved in the impaired local cerebral blood flow after thrombolysis.
AuthorsK Umemura, M Ishiye, K Kosuge, M Nakashima
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 275 Issue 1 Pg. 17-21 (Feb 24 1995) ISSN: 0014-2999 [Print] Netherlands
PMID7774658 (Publication Type: Journal Article)
Chemical References
  • Azepines
  • Endothelin Receptor Antagonists
  • Endothelins
  • Indoles
  • FR 139317
  • lanoteplase
  • Tissue Plasminogen Activator
Topics
  • Animals
  • Azepines (administration & dosage, pharmacology, therapeutic use)
  • Blood Platelets (drug effects)
  • Brain (metabolism)
  • Cell Adhesion (drug effects)
  • Cerebral Arterial Diseases (drug therapy, prevention & control)
  • Cerebral Infarction (drug therapy)
  • Cerebrovascular Circulation (drug effects)
  • Disease Models, Animal
  • Endothelin Receptor Antagonists
  • Endothelins (analysis, metabolism)
  • Indoles (administration & dosage, pharmacology, therapeutic use)
  • Intracranial Embolism and Thrombosis (drug therapy)
  • Male
  • Radioimmunoassay
  • Rats
  • Rats, Wistar
  • Tissue Plasminogen Activator (administration & dosage, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: